# A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

> **NCT03959488** · PHASE2,PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 925 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** MEDI8897
- **DRUG:** Palivizumab

## Key facts

- **NCT ID:** NCT03959488
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-30
- **Primary completion:** 2021-05-03
- **Final completion:** 2023-01-20
- **Target enrollment:** 925 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03959488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03959488, "A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03959488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*